Cerus reports Q1 EPS (4c) vs. (5c) last year

Reports Q1 revenue $48.9M, consensus $47.4M. “We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus (CERS)’ mission to transform the safety and availability of transfused blood components,” said William “Obi” Greenman, Cerus’ president and chief executive officer. “We delivered 13% first quarter product revenue growth, in-line with our Q1 guidance, received CE Mark for the INT200, our next generation LED-based illumination device ahead of plan, and most recently, we have submitted our updated CE Mark application for the INTERCEPT red blood cell system to TundefinedV-SundefinedD, our notified body. Based on revenue growth prospects for 2025 and beyond, our expected gross margin profile, and demonstrated financial discipline, we believe we are in a position to deliver operating cash flow to fuel our growth and make INTERCEPT the standard of care for blood safety globally.”